Merck and Moderna maintain a decade-long 50/50 partnership on intismeran autogene, their individualized mRNA neoantigen therapy paired with Keytruda, which delivered statistically significant Phase 3 recurrence-free and distant metastasis-free survival benefits in resected melanoma at an August 2026 interim readout. This collaboration continues without signs of escalation toward full ownership, even as analysts note strategic logic for Merck to consolidate economics ahead of its flagship drug’s 2028 patent pressures. Merck has instead pursued separate multibillion-dollar deals, such as its recent Cidara acquisition, while Moderna’s shares have rallied sharply on the data. Full Phase 3 results are slated for October at ESMO, but the absence of reported talks or filings supports the market-implied 86.2% probability against a 2026 merger announcement.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於是
12% 機率
最新
最新
2026-12-31
是
12% 機率
最新
最新
2026-12-31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-long 50/50 partnership on intismeran autogene, their individualized mRNA neoantigen therapy paired with Keytruda, which delivered statistically significant Phase 3 recurrence-free and distant metastasis-free survival benefits in resected melanoma at an August 2026 interim readout. This collaboration continues without signs of escalation toward full ownership, even as analysts note strategic logic for Merck to consolidate economics ahead of its flagship drug’s 2028 patent pressures. Merck has instead pursued separate multibillion-dollar deals, such as its recent Cidara acquisition, while Moderna’s shares have rallied sharply on the data. Full Phase 3 results are slated for October at ESMO, but the absence of reported talks or filings supports the market-implied 86.2% probability against a 2026 merger announcement.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
市場開放時間： Aug 19, 2026, 3:58 PM ET
交易量
$467結束日期
2027-01-01市場開放時間
Aug 19, 2026, 3:58 PM ETThis market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna maintain a decade-long 50/50 partnership on intismeran autogene, their individualized mRNA neoantigen therapy paired with Keytruda, which delivered statistically significant Phase 3 recurrence-free and distant metastasis-free survival benefits in resected melanoma at an August 2026 interim readout. This collaboration continues without signs of escalation toward full ownership, even as analysts note strategic logic for Merck to consolidate economics ahead of its flagship drug’s 2028 patent pressures. Merck has instead pursued separate multibillion-dollar deals, such as its recent Cidara acquisition, while Moderna’s shares have rallied sharply on the data. Full Phase 3 results are slated for October at ESMO, but the absence of reported talks or filings supports the market-implied 86.2% probability against a 2026 merger announcement.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
交易量
$467結束日期
2027-01-01市場開放時間
Aug 19, 2026, 3:58 PM ETMerck and Moderna maintain a decade-long 50/50 partnership on intismeran autogene, their individualized mRNA neoantigen therapy paired with Keytruda, which delivered statistically significant Phase 3 recurrence-free and distant metastasis-free survival benefits in resected melanoma at an August 2026 interim readout. This collaboration continues without signs of escalation toward full ownership, even as analysts note strategic logic for Merck to consolidate economics ahead of its flagship drug’s 2028 patent pressures. Merck has instead pursued separate multibillion-dollar deals, such as its recent Cidara acquisition, while Moderna’s shares have rallied sharply on the data. Full Phase 3 results are slated for October at ESMO, but the absence of reported talks or filings supports the market-implied 86.2% probability against a 2026 merger announcement.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions